Imaging study indicates 99mTc-maraciclatide is a promising diagnostic and monitoring tool for endometriosis
Serac Healthcare, a clinical radiopharmaceutical company developing the molecular imaging agent 99mTc-maraciclatide, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford have had phase 2 data published from the DETECT (Detecting endometriosis expressed integrins using technetium-99m) imaging study. Published online in The Lancet Obstetrics, Gynaecology & Women’s Health, the study […]
Read More